{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:51:01Z","timestamp":1789008661946,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.clml.2017.06.006","type":"journal-article","created":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T08:47:58Z","timestamp":1497689278000},"page":"488-497.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy"],"prefix":"10.1016","volume":"17","author":[{"given":"Ji","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy C.","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Aoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Bierman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Bociek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O.","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis D.","family":"Weisenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.06.006_bib1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A\u00a0clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.006_bib2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-Hodgkin lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project","volume":"9","author":"Anderson","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.06.006_bib3","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"358","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.clml.2017.06.006_bib4","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","article-title":"National Cancer Institute sponsored study of classifications of non-Hodgkin lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project","volume":"49","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.06.006_bib5","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood-2002-07-2298","article-title":"A\u00a0significant diffuse component predicts for inferior survival in Grade 3 follicular lymphoma, but cytologic subtypes do not predict survival","volume":"101","author":"Hans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.006_bib6","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A\u00a0predictive model for aggressive non-Hodgkin lymphoma","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.06.006_bib7","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.006_bib8","first-page":"89","article-title":"Prognostic factors in follicular lymphomas","volume":"20","author":"Coiffier","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2017.06.006_bib9","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1200\/JCO.1994.12.7.1340","article-title":"Is the International Prognostic Index for aggressive lymphoma patients useful for follicular lymphoma patients?","volume":"12","author":"Bastion","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.006_bib10","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.006_bib11","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.006_bib12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mds429","article-title":"Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices","volume":"24","author":"Nooka","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.06.006_bib13","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1182\/blood-2005-01-0053","article-title":"Does the FLIPI apply to Grade 3 follicular lymphoma?","volume":"105","author":"Ghielmini","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.006_bib14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/annonc\/mdm511","article-title":"The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular Grade 3 lymphoma","volume":"19","author":"Overman","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.06.006_bib15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clml.2014.04.008","article-title":"Follicular lymphoma Grade 3: review and updates","volume":"14","author":"Vaidyanathan","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2017.06.006_bib16","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1200\/JCO.1997.15.4.1654","article-title":"Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Wendum","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.006_bib17","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/blood.V93.7.2202","article-title":"Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features","volume":"93","author":"Rodriguez","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.006_bib18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/CCO.0b013e3282c9ad78","article-title":"Natural history of follicular grade 3 non-Hodgkin lymphoma","volume":"19","author":"Bierman","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clml.2017.06.006_bib19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2141.2011.08942.x","article-title":"Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times","volume":"156","author":"Wahlin","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.06.006_bib20","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdl039","article-title":"Patients with Grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience","volume":"17","author":"Ganti","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.06.006_bib21","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/blood.V87.10.4358.bloodjournal87104358","volume":"87","author":"Pittaluga","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.006_bib22","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0889-8588(05)70468-8","article-title":"Follicular lymphomas: do histologic subtypes predict outcome?","volume":"11","author":"Miller","year":"1997","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2017.06.006_bib23","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/bjh.13502","article-title":"Clinico-biological features, treatment and survival of 457 patients with histological Grades 3A and 1-2 follicular lymphoma mostly treated with immunochemotherapy","volume":"172","author":"Mercadal","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.06.006_bib24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/sj.bjc.6601006","article-title":"Outcome of follicular lymphoma Grade 3: is anthracycline necessary as front-line therapy?","volume":"89","author":"Chau","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2017.06.006_bib25","doi-asserted-by":"crossref","first-page":"863","DOI":"10.5858\/2004-128-863-ACEOFL","article-title":"A\u00a0clinicopathologic evaluation of follicular lymphoma Grade 3A versus Grade 3B reveals no survival differences","volume":"128","author":"Hsi","year":"2004","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clml.2017.06.006_bib26","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/annonc\/mdq574","article-title":"Follicular non-Hodgkin lymphoma Grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy","volume":"22","author":"Shustik","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.06.006_bib27","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.006_bib28","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.006_bib29","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.006_bib30","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.006_bib31","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.006_bib32","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/leu.2014.251","article-title":"Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study","volume":"29","author":"Junlen","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.06.006_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.2130","article-title":"Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up","volume":"33","author":"Nicolas-Virelizier","year":"2015","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2017.06.006_bib34","first-page":"4","article-title":"Comparison of front-line chemotherapy for aggressive non-Hodgkin lymphoma using the CAP-BOP regimens. The Nebraska Lymphoma Study Group","volume":"31","author":"Vose","year":"1994","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2017.06.006_bib35","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.humpath.2013.06.013","article-title":"Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy","volume":"44","author":"Maeshima","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clml.2017.06.006_bib36","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/annonc\/mdw185","article-title":"Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL","volume":"27","author":"Koch","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.06.006_bib37","first-page":"121","article-title":"Standard R-CHOP therapy in follicular lymphoma and diffuse large B-cell lymphoma","volume":"53","author":"Tomita","year":"2013","journal-title":"J\u00a0Clin Exp Hematol"},{"key":"10.1016\/j.clml.2017.06.006_bib38","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V99.10.3806","article-title":"Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3","volume":"99","author":"Ott","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.006_bib39","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0002-9440(10)63313-5","article-title":"Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component","volume":"165","author":"Katzenberger","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clml.2017.06.006_bib40","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.2011.042531","article-title":"Follicular lymphoma Grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles","volume":"96","author":"Horn","year":"2011","journal-title":"Haematologica"},{"issue":"suppl 2","key":"10.1016\/j.clml.2017.06.006_bib41","first-page":"327A","article-title":"Follicular large cleaved cell lymphoma is a distinctive morphological and clinical variant of follicular lymphoma","volume":"26","author":"El Behery","year":"2013","journal-title":"Mod Pathol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017308042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017308042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:13Z","timestamp":1761870553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017308042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S2152265017308042"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.06.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}